Literature DB >> 15964661

Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors.

Mortimer Korf1, Dominik Jarczak, Carmela Beger, Michael P Manns, Martin Krüger.   

Abstract

BACKGROUND/AIMS: Small interfering RNAs (siRNAs) are an efficient tool to specifically inhibit gene expression by RNA interference. Since hepatitis C virus (HCV) replicates in the cytoplasm of liver cells without integration into the host genome, RNA-directed antiviral strategies are likely to successfully block the HCV replication cycle. Additional benefit might arise from inhibition of cellular cofactors of HCV replication, such as proteasome alpha-subunit 7 (PSMA7) or Hu antigen R (HuR).
METHODS: In this study, we investigated direct and cofactor-mediated inhibition of HCV by a panel of DNA-based retroviral vectors expressing siRNAs against highly conserved HCV sequences or the putative HCV cofactors PSMA7 and HuR. Effects were determined in HCV IRES-mediated translation assays and subgenomic HCV replicon cells.
RESULTS: PSMA7- and HuR-directed siRNAs successfully inhibited expression of the endogenous genes, and PSMA7 and HuR silencing significantly diminished HCV replicon RNA and NS5B protein levels. HCV-directed siRNAs substantially inhibited HCV IRES-mediated translation and subgenomic HCV replication. Combinations of PSMA7- and HuR-directed siRNAs with HCV-directed siRNAs revealed additive HCV RNA inhibitory effects in monocistronic replicon cells.
CONCLUSIONS: A dual approach of direct- and cofactor-mediated inhibition of HCV replication might avoid selection of mutants and thereby become a powerful strategy against HCV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964661     DOI: 10.1016/j.jhep.2005.02.046

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

Review 1.  Transcriptional regulation of mammalian miRNA genes.

Authors:  Brian C Schanen; Xiaoman Li
Journal:  Genomics       Date:  2010-10-23       Impact factor: 5.736

Review 2.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

3.  Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.

Authors:  Pruksa Nawtaisong; Mark E Fraser; James R Carter; Malcolm J Fraser
Journal:  Virology       Date:  2015-04-07       Impact factor: 3.616

4.  All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution.

Authors:  Dirk Grimm
Journal:  Mol Ther       Date:  2012-09       Impact factor: 11.454

Review 5.  Landscape of post-transcriptional gene regulation during hepatitis C virus infection.

Authors:  Johannes Schwerk; Abigail P Jarret; Rochelle C Joslyn; Ram Savan
Journal:  Curr Opin Virol       Date:  2015-04-15       Impact factor: 7.090

Review 6.  Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines.

Authors:  Jinho Park; Joonyoung Park; Yihua Pei; Jun Xu; Yoon Yeo
Journal:  Adv Drug Deliv Rev       Date:  2015-12-10       Impact factor: 15.470

7.  Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect.

Authors:  Tatsuo Kanda; Robert Steele; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 8.  The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.

Authors:  You Li; Daisuke Yamane; Takahiro Masaki; Stanley M Lemon
Journal:  Nat Rev Microbiol       Date:  2015-08-10       Impact factor: 60.633

9.  Stable replication of the EBNA1/OriP-mediated baculovirus vector and its application to anti-HCV gene therapy.

Authors:  Hitoshi Suzuki; Norihiko Matsumoto; Tomoyuki Suzuki; Myint Oo Chang; Hiroshi Takaku
Journal:  Virol J       Date:  2009-10-02       Impact factor: 4.099

10.  Refractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivo.

Authors:  Dominique L Ouellet; Isabelle Plante; Vincent Boissonneault; Cherifa Ayari; Patrick Provost
Journal:  J Negat Results Biomed       Date:  2009-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.